Abstract
Shilajit is a naturally occurring resinous exudate with centuries of documented use in Ayurvedic medicine. Its principal bioactive constituents — fulvic acid and a proprietary aromatic compound complex termed shilarathenes™, comprising urolithin metabolites, phenolic acids, and flavonoids — are proposed to enhance mitochondrial ATP synthesis, attenuate exercise-induced muscle damage, and modulate androgen biosynthesis. Prior controlled trials have demonstrated increases in testosterone and retention of muscular strength with purified shilajit, though large trials in resistance-trained populations have been absent.
In this randomised, double-blind, placebo-controlled, multicenter trial (CTRI/2025/07/091323), 100 healthy males aged 21–50 years (BMI <30 kg/m²; ≥1 year of resistance training) were enrolled across four sites. Participants received 250 mg twice daily of standardised TruBlk™ Shilajit resin (≥60% fulvic acid; ≥10% shilarathenes™) or matched placebo for 90 days, and were instructed to maintain habitual training and dietary practices throughout. Primary endpoints were changes from baseline in 1RM leg press, muscle endurance, RPE, and DOMS. Secondary endpoints included VO₂max, testosterone, creatine kinase, lactate dehydrogenase, handgrip strength, and global improvement ratings.
Ninety-nine participants completed the trial (99% retention). All primary outcomes showed significantly steeper improvement in the active group, assessed by treatment × time interaction: 1RM leg press (+26.0% vs +18.4%; p=0.0003, d=0.74), muscle endurance (+110.8% vs +80.5%; p=0.0017, d=0.60), RPE (p=0.002), and DOMS (p=0.036). Dominant handgrip strength showed the largest secondary effect (+12.5% vs +7.9%; p=0.0002, d=0.77). The active group also demonstrated greater reductions in creatine kinase (−33.6% vs −6.9%; p=0.030, δ=−0.26) and lactate dehydrogenase (−17.8% vs −4.2%; p=0.039, δ=−0.24), greater increases in free testosterone (+21.8% vs −2.9%; p=0.030, d=0.45) and total testosterone (+15.6% vs −3.8%; p=0.038, d=0.43), and a modest improvement in VO₂max (+3.8% vs +2.9%; p=0.032, d=0.41) compared with placebo. No adverse events were recorded in the active group.
Ninety days of TruBlk™ Shilajit resin supplementation produced robust improvements in muscle strength and endurance in resistance-trained males, with moderate effect sizes for the strength outcomes. These data support TruBlk™ Shilajit resin as a safe and promising ergogenic agent meriting further clinical evaluation.
Competing Interest Statement
This study was funded by Amaara Botanicals Private Limited, manufacturer of the TruBlk Shilajit resin evaluated in this trial. DY and AS are founders of Amaara Botanicals Private Limited. RG is an employee of Amaara Botanicals Private Limited. KMS is a consultant to Amaara Botanicals Private Limited. AC, SM, SG, and PC served as clinical site investigators at their respective institutions. MK and STR are affiliated with Auriga Research Pvt Ltd, an independent contract research organization engaged by Amaara Botanicals to support trial conduct. No clinical site investigators or CRO-affiliated authors have any other financial or ownership relationship with Amaara Botanicals beyond trial-related conduct fees, if any. No other relationships or activities that could appear to have influenced the submitted work.
Clinical Trial
CTRI/2025/07/091323
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol, amendments, participant information sheet, consent form, and other study-specific documents were reviewed and approved by two Institutional/Independent Ethics Committees: the Good Society Ethical Research (GSER) Committee (Registration No. ECR/69/Indt/DL/2013/RR-24; approved 10-Jul-2025) and the Aakash Healthcare Institutional Ethics Committee (Registration No. ECR/1265/Inst/DL/2019/RR-24; approved 01-Aug-2025). The trial was registered with the Clinical Trials Registry-India (CTRI) prior to enrolment of the first participant (CTRI Registration No. CTRI/2025/07/091323). Written informed consent, compliant with the Declaration of Helsinki, ICH GCP, and local regulations, was obtained from each participant prior to enrolment, and a signed copy was provided to each participant.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
